Literature DB >> 30942463

A novel NHS mutation in a Chinese family with Nance‑Horan Syndrome.

Meirong Wei1, Anhui Qi2, Haiming Mo1, Kailin Wu1, Xu Ma3, Binbin Wang2.   

Abstract

NanceHoran syndrome (NHS) is a rare X‑linked disorder with various clinical manifestations. The present study aimed to identify the pathogenic mutation causing NHS in a three‑generation Chinese family with 4 individuals presenting primarily with congenital cataracts. The genomic DNA of 5 individuals was collected, and family history and clinical information were recorded. Whole exome sequencing was performed on the proband, and candidate mutations were filtered by a series of screening processes and validated by Sanger sequencing. The identified pathogenic mutation was confirmed by co‑segregation analysis. Finally, a novel frameshift mutation (NM_001291867.1: c.302dupA; p.Ala102fs) was identified in the NHS actin remodeling regulator (NHS) gene, which co‑segregated with congenital cataracts in this family. Carrier females exhibited similar but milder clinical symptoms compared with the affected male. These clinical symptoms were consistent with the phenotypic features of the NHS‑associated disease, NHS. In summary, the present study identified a novel NHS mutation in a Chinese family with atypical NHS; the results broaden the known pathogenic mutation spectrum of NHS and will aid in the genetic counseling of patients with NHS. The data from the present study also suggest that genetic analysis may be required for the diagnosis of this disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30942463     DOI: 10.3892/mmr.2019.10106

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  A novel Nance-Horan syndrome mutation identified by next-generation sequencing in a Chinese family.

Authors:  Hong-Yan Sun; Hong-Jing Zhu; Ru-Xu Sun; Ying Wang; Jia-Nan Wang; Bing Qin; Wei-Wei Zhang; Jiang-Dong Ji
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.